Evox Therapeutics Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 135

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $95M

  • Investors
  • 13

Evox Therapeutics General Information

Description

Developer of exosome-based therapeutics designed to treat various life-threatening rare diseases with profound implications for human health. The company's therapeutics use nucleic acid and protein delivery technology to harness and engineer the natural trafficking capabilities of extracellular vesicles, enabling healthcare providers to leverage proprietary targeting, manufacturing processes and purification methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Oxford Science Park, Medawar Centre
  • 2nd Floor East Building, Robert Robinson Avenue
  • Oxford OX4 4HG
  • England, United Kingdom
+44 01865 000000

Evox Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evox Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 18-Feb-2021 $95M 00000 00000 Completed Generating Revenue
3. Grant 22-Mar-2019 00.000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 03-Sep-2018 $45.6M $60.2M 000.00 Completed Generating Revenue
1. Seed Round 10-May-2016 $14.6M $14.6M 0000 Completed Clinical Trials - Phase 1
To view Evox Therapeutics’s complete valuation and funding history, request access »

Evox Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Preferred 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
A Preferred 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 224,496 $0.013743 $61.84 $61.84 1x $61.84 22.16%
To view Evox Therapeutics’s complete cap table history, request access »

Evox Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of exosome-based therapeutics designed to treat various life-threatening rare diseases with profound implicati
Biotechnology
Oxford, United Kingdom
135 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
Brisbane, CA
000 As of 0000
00000
000000000 00000

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repr
0000 000000000
Ghent, Belgium
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evox Therapeutics Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sangamo Therapeutics Formerly VC-backed Brisbane, CA 000 00000 000000000 00000
000000 00000000000 Venture Capital-Backed Ghent, Belgium 00 00000 00000000000 00000
000000 0000 Corporation Miramar, FL 00 000000000 -
000000 Venture Capital-Backed Seattle, WA 00 00000 0000000000 00000
00000 000000000000 Venture Capital-Backed Woburn, MA 0 00.00 0000000000 0 00.00
You’re viewing 5 of 34 competitors. Get the full list »

Evox Therapeutics Patents

Evox Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202118946-D0 Engineered extracellular vesicles with improved cargo delivery Pending 23-Dec-2021
GB-202107182-D0 Nanoparticle delivery system for production of engineered extracellular vesicles Pending 19-May-2021
GB-202105925-D0 Modified extracellular vesicles (evs) with improved half-life Pending 26-Apr-2021
GB-202015399-D0 Engineered extracellular vesicles displaying enhanced pharmacokinetics Inactive 29-Sep-2020 000000000
GB-202010278-D0 Extracellular vesicles with improved half-life Inactive 03-Jul-2020 A61K9/5068
To view Evox Therapeutics’s complete patent history, request access »

Evox Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Antonin de Fougerolles Ph.D Chief Executive Officer & Board Member
Per Lundin Ph.D Co-Founder, Chief Business Officer& Board Member
Samir El-Andaloussi Co-Founder & Advisor
Matthew Wood MD Co-Founder & Board Observer
Sonya Montgomery Chief Medical Officer
To view Evox Therapeutics’s complete executive team members history, request access »

Evox Therapeutics Board Members (14)

Name Representing Role Since
Amrit Nagpal Redmile Group Board Member 000 0000
Antonin de Fougerolles Ph.D Evox Therapeutics Chief Executive Officer & Board Member 000 0000
Chau Khuong Self Board Member 000 0000
John McHutchison MD Self Board Member 000 0000
Kevin Raidy Cowen Healthcare Investments Board Observer 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Evox Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evox Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OrbiMed PE/Buyout Minority 000 0000 000000 0
Skyviews Life Science Venture Capital Minority 000 0000 000000 0
The Invus Group PE/Buyout Minority 000 0000 000000 0
Duchenne UK Corporation 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »